This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): oral ceftriaxone, ceftriaxone sodium
Description: Ceftriaxone is a third generation cephalosporin antibiotic. Third generation cephalosporins have greater Gram-(-) activity than first or second generation cephalosporins. Good activity is observed against streptococci and enteric Gram-(-) rods. Moderate activity is observed against methicillin sensitive strains of Staphyloccocus aureus, and relatively modest activity against Pseudomonas, anaerobes, and methicillin-resistant S. aureus.
Third generation cephalosporins are among the antibiotic classes most strongly associated with Clostridium difficile associated diarrhea.
In November 2000, Cubist Pharmaceuticals announced that it has acquired worldwide rights to oral ceftriaxone from International Health Management Associates (IHMA). This formulation is an orally active version of Roche's Rocephin. Terms of the acquisition were not disclosed.
Merck and Cubist
In December 2014, Merck and Cubist Pharmaceuticals announced that the companies have entered into a definitive agreement under which Merck will acquire Cubist for $102 per share in cash. Unanimously approved by the boards of directors of both companies, the transaction has an equity valuation of $8.4 billion and will also include $1.1 billion in net debt (based on projected cash balances) and other considerations for a total transaction value of approximately $9.5 billion.
In January 2015, Merck announced the successful completion of the tender offer for all of the outstanding shares of common stock of...See full deal structure in Biomedtracker
Additional information available to subscribers only: